Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences (GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $68.58
  • 50 Day Moving Average: $67.30
  • 200 Day Moving Average: $71.44
  • 52-Week Range: $65.38 - $100.75
  • Trailing P/E Ratio: 6.90
  • Foreward P/E Ratio: 9.08
  • P/E Growth: -1.71
  • Market Cap: $89.64B
  • Outstanding Shares: 1,307,066,000
  • Beta: 1.11
Profitability:
  • Net Margins: 44.43%
  • Return on Equity: 92.36%
  • Return on Assets: 29.22%
Debt:
  • Debt-to-Equity Ratio: 1.53%
  • Current Ratio: 4.17%
  • Quick Ratio: 4.00%

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 10 Hold Ratings, 15 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.65)
Consensus Price Target: $83.49 (21.74% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/26/2017William BlairReiterated RatingOutperformLowView Rating Details
4/24/2017Stifel NicolausReiterated RatingBuy$87.00LowView Rating Details
4/23/2017Barclays PLCReiterated RatingOverweight$90.00 -> $85.00MediumView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
4/21/2017Maxim GroupReiterated RatingHoldLowView Rating Details
4/17/2017Cowen and CompanyReiterated RatingBuy$100.00LowView Rating Details
4/6/2017Jefferies Group LLCReiterated RatingBuy$82.00LowView Rating Details
4/6/2017JPMorgan Chase & Co.Reiterated RatingOverweight$82.00LowView Rating Details
3/15/2017Credit Suisse Group AGReiterated RatingOutperform$79.00LowView Rating Details
3/13/2017Bank of America CorpReiterated RatingNeutral$76.00 -> $68.19LowView Rating Details
3/13/2017Goldman Sachs Group IncReiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
3/1/2017MizuhoLower Price TargetBuy$88.00 -> $77.00N/AView Rating Details
2/14/2017Berenberg BankSet Price TargetBuy$112.00 -> $78.00N/AView Rating Details
2/8/2017Leerink SwannSet Price TargetHold$91.00 -> $74.00N/AView Rating Details
2/9/2017BMO Capital MarketsReiterated RatingHold$88.00 -> $75.00N/AView Rating Details
2/8/2017Royal Bank of CanadaLower Price Target$75.00N/AView Rating Details
2/8/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/8/2017Robert W. BairdReiterated RatingOutperform$87.00N/AView Rating Details
2/8/2017Citigroup IncDowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
2/8/2017Morgan StanleyLower Price TargetEqual Weight$85.00 -> $77.00N/AView Rating Details
2/8/2017Wells Fargo & CoReiterated RatingMarket Perform$79.50 -> $65.50N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
9/23/2016GabelliReiterated RatingBuyN/AView Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$120.00 -> $116.00N/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00N/AView Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00N/AView Rating Details
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00N/AView Rating Details
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00N/AView Rating Details
(Data available from 4/28/2015 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)
Earnings History by Quarter for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017        
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
2017 EPS Consensus Estimate: $8.09
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.09$2.42$2.23
Q2 20173$2.01$2.25$2.10
Q3 20173$1.88$2.02$1.93
Q4 20173$1.79$1.86$1.82
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Most Recent Dividend:3/30/2017
Annual Dividend:$1.88
Dividend Yield:2.74%
Payout Ratio:18.91% (Trailing 12 Months of Earnings)
22.79% (Based on This Year's Estimates)
24.90% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History by Quarter for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/7/2017quarterly$0.523.11%3/14/20173/16/20173/30/2017
11/1/2016quarterly$0.472.59%12/13/201612/15/201612/29/2016
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 74.19%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.94View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Gilead Sciences (NASDAQ:GILD)
Latest Headlines for Gilead Sciences (NASDAQ:GILD)
Source:
DateHeadline
finance.yahoo.com logoGilead Sciences, Inc. breached its 50 day moving average in a Bullish Manner : GILD-US : April 27, 2017
finance.yahoo.com - April 27 at 6:00 PM
finance.yahoo.com logoGilead earnings: Lowered expectations could help when company reports first-quarter results
finance.yahoo.com - April 27 at 6:00 PM
finance.yahoo.com logoMixed bag for biotech earnings
finance.yahoo.com - April 27 at 6:00 PM
finance.yahoo.com logoGilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates? - Yahoo Finance
finance.yahoo.com - April 27 at 12:59 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Receives "Outperform" Rating from William Blair
www.americanbankingnews.com - April 26 at 9:30 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Very Likely to Affect Gilead Sciences (GILD) Stock Price
www.americanbankingnews.com - April 26 at 9:28 PM
finance.yahoo.com logoGilead Sciences: Is the Bottom In?
finance.yahoo.com - April 26 at 7:57 PM
americanbankingnews.com logoGilead Sciences Sees Unusually Large Options Volume (GILD)
www.americanbankingnews.com - April 26 at 2:52 PM
americanbankingnews.com logoGilead Sciences Target of Unusually Large Options Trading (GILD)
www.americanbankingnews.com - April 26 at 2:29 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Downgraded by Vetr Inc.
www.americanbankingnews.com - April 26 at 12:14 AM
finance.yahoo.com logoGilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?
finance.yahoo.com - April 25 at 5:00 PM
seekingalpha.com logoGilead Sciences: A Future Dividend Gold Mine At A Bargain Price
seekingalpha.com - April 24 at 5:12 PM
finance.yahoo.com logoGilead Sciences: Know Hope…or No Hope?
finance.yahoo.com - April 24 at 5:12 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - April 24 at 4:00 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 24 at 2:54 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Upgraded to Strong-Buy at Vetr Inc.
www.americanbankingnews.com - April 24 at 1:45 PM
fool.com logoBetter Buy: Gilead Sciences vs. Celgene
www.fool.com - April 24 at 1:38 PM
americanbankingnews.com logoQ1 2017 EPS Estimates for Gilead Sciences, Inc. Raised by Analyst (GILD)
www.americanbankingnews.com - April 24 at 7:25 AM
americanbankingnews.com logoPositive News Coverage Very Likely to Affect Gilead Sciences (GILD) Stock Price
www.americanbankingnews.com - April 23 at 10:25 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Given "Overweight" Rating at Barclays PLC
www.americanbankingnews.com - April 23 at 2:02 PM
fool.com logoShould Gilead Sciences Be Worried About Allergan?
www.fool.com - April 23 at 12:11 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Given Buy Rating at Piper Jaffray Companies
www.americanbankingnews.com - April 21 at 6:16 PM
finance.yahoo.com logoGilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
finance.yahoo.com - April 21 at 5:24 PM
finance.yahoo.com logoGilead Sciences: Just Like Thermopylae?
finance.yahoo.com - April 21 at 5:24 PM
streetinsider.com logoGilead Sciences (GILD) Reports POC Data for GS-0976 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017
www.streetinsider.com - April 21 at 11:27 AM
finance.yahoo.com logoGilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
finance.yahoo.com - April 21 at 11:27 AM
americanbankingnews.com logoGilead Sciences (GILD) Receiving Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 20 at 10:37 PM
finance.yahoo.com logoGilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
finance.yahoo.com - April 20 at 12:08 PM
finance.yahoo.com logoGilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
finance.yahoo.com - April 20 at 12:08 PM
seekingalpha.com logoGilead Sciences Near 3-Year Low. Time To Buy?
seekingalpha.com - April 19 at 10:20 PM
finance.yahoo.com logoThe Better Big Pharma Stock: AbbVie or Gilead?
finance.yahoo.com - April 19 at 11:52 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Upgraded at Vetr Inc.
www.americanbankingnews.com - April 19 at 12:29 AM
nasdaq.com logoCommit To Buy Gilead Sciences At $35, Earn 2.7% Using Options
www.nasdaq.com - April 18 at 5:01 PM
finance.yahoo.com logoGilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017
finance.yahoo.com - April 18 at 5:01 PM
finance.yahoo.com logoHere's The Real Reason Gilead Sciences Is So Incredibly Cheap
finance.yahoo.com - April 18 at 11:28 AM
americanbankingnews.com logoGilead Sciences (GILD) Getting Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 17 at 8:21 PM
finance.yahoo.com logoFDA Complete Response Smacks LLY & INCY, What Now?
finance.yahoo.com - April 17 at 4:55 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Receives Buy Rating from Cowen and Company
www.americanbankingnews.com - April 17 at 12:24 PM
finance.yahoo.com logoGilead, Pfizer, AbbVie Win From Lilly's Loss
finance.yahoo.com - April 17 at 11:20 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 11:10 AM
americanbankingnews.com logoRoyal Bank of Canada Reiterates Buy Rating for Gilead Sciences, Inc. (GILD)
www.americanbankingnews.com - April 16 at 12:52 PM
fool.com logoWhy Gilead Sciences Could Be a Gold Mine for Value Investors
www.fool.com - April 16 at 11:16 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Effect Gilead Sciences (GILD) Stock Price
www.americanbankingnews.com - April 14 at 9:09 PM
americanbankingnews.com logoQ1 2017 EPS Estimates for Gilead Sciences, Inc. (GILD) Boosted by Leerink Swann
www.americanbankingnews.com - April 14 at 8:40 AM
finance.yahoo.com logoThe Hot Stock: Alexion Pharmaceuticals Climbs 3.3%
finance.yahoo.com - April 13 at 5:16 PM
americanbankingnews.com logoBrokers Set Expectations for Gilead Sciences, Inc.'s Q4 2017 Earnings (GILD)
www.americanbankingnews.com - April 13 at 12:10 PM
finance.yahoo.com logoBiotech ETFs To Consider Ahead of Earnings Season
finance.yahoo.com - April 12 at 5:29 PM
americanbankingnews.com logo$6.57 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter
www.americanbankingnews.com - April 12 at 12:35 PM
finance.yahoo.com logoFirst Quarter Earnings Preview: Biotech Heavyweights
finance.yahoo.com - April 12 at 9:44 AM
zacks.com logoGilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion
www.zacks.com - April 10 at 5:11 PM

Social

Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, February 7th. Shareholders of record on Thursday, March 16th will be given a dividend of $0.52 per share on Thursday, March 30th. This represents a $2.08 annualized dividend and a yield of 3.03%. The ex-dividend date is Tuesday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.47.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its earnings results on Tuesday, February, 7th. The company reported $2.70 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $2.61 by $0.09. The firm earned $7.30 billion during the quarter, compared to the consensus estimate of $7.16 billion. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. The company's revenue for the quarter was down 13.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.32 earnings per share.

When will Gilead Sciences make its next earnings announcement?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

26 analysts have issued twelve-month price objectives for Gilead Sciences' shares. Their predictions range from $65.50 to $116.00. On average, they expect Gilead Sciences' stock price to reach $83.49 in the next twelve months.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. Maxim Group analysts commented, "Gilead announced positive data for GS-0976 at the 53rd Annual Meeting of the European Association for the Study of the Liver (EASL) during the International Liver Congress (ILC), demonstrating significant improvements in liver fat content and noninvasive markers of fibrosis in 10 NASH patients." (4/21/2017)
  • 2. According to Zacks Investment Research, "Gilead is a dominant player in the HIV market with a strong portfolio. Gilead is currently looking to introduce drugs with improved long-term safety profiles in the HIV market. The newly launched TAF-based products – Genvoya, Odefsey and Descovy are performing well in both the U.S. and EU. The company expects that the use of Truvada for pre-exposure prophylaxis (PrEP) will continue to boost sales of HIV franchise going forward, particularly in the U.S. However, the company’s HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales. The company expects a further decline in patients starts in 2017. In addition, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. Shares of Gilead underperformed the biotech industry in the past one year. On a positive note, Epclusa’s uptake has been encouraging." (4/11/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
  • 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)
  • 5. Needham & Company LLC analysts commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD." (2/8/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a decline in short interest during the month of March. As of March 15th, there was short interest totalling 12,801,714 shares, a decline of 5.3% from the February 28th total of 13,513,446 shares. Based on an average daily trading volume, of 9,065,654 shares, the days-to-cover ratio is presently 1.4 days.

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Manhattan Co. (0.20%), Bank of Montreal Can (0.19%), State of New Jersey Common Pension Fund D (0.13%), Candriam Luxembourg S.C.A. (0.12%), Strs Ohio (0.11%) and PGGM Investments (0.10%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including Waverton Investment Management Ltd, Korea Investment CORP, State of New Jersey Common Pension Fund D, Old Mutual Global Investors UK Ltd., Glen Harbor Capital Management LLC, First Quadrant L P CA, Cullen Frost Bankers Inc. and Smith Chas P & Associates PA Cpas. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Hexavest Inc., Bank of Montreal Can, GW Henssler & Associates Ltd., ANTIPODES PARTNERS Ltd, Doyle Wealth Management, Edge Wealth Management LLC and Conning Inc..

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Gilead Sciences stock cost?

One share of Gilead Sciences stock can currently be purchased for approximately $68.58.

Gilead Sciences (GILD) Chart for Friday, April, 28, 2017

This page was last updated on 4/28/2017 by MarketBeat.com Staff